Moreover, increased BCL2 correlated with failure to achieve complete remission (CR) and with shorter overall survival (OS) of AML patients, making it an important therapeutic target.12,13 Indeed, these findings led to the design of potent and selective BCL2-inhibitor, venetoclax. The gene discussed is BCL2; the disease is acute myeloid leukemia.